Summary:
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD.
Qualified Participants Must:
• Have memory loss
• Between ages of 55-85
• Have availability of a study partner
Qualified Participants May Receive:
May receive compensation for time and travel.